Compare Boule Diagnostics AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 146 Million (Micro Cap)
83.00
NA
0.00%
0.99
2.26%
0.83
Revenue and Profits:
Net Sales:
112 Million
(Quarterly Results - Jun 2026)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.14%
0%
4.14%
6 Months
-23.31%
0%
-23.31%
1 Year
-44.3%
0%
-44.3%
2 Years
-60.8%
0%
-60.8%
3 Years
-64.41%
0%
-64.41%
4 Years
-80.12%
0%
-80.12%
5 Years
-91.65%
0%
-91.65%
Boule Diagnostics AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.10%
EBIT Growth (5y)
0.15%
EBIT to Interest (avg)
-1.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.04
Sales to Capital Employed (avg)
1.26
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.59%
ROE (avg)
5.22%
Valuation key factors
Factor
Value
P/E Ratio
83
Industry P/E
Price to Book Value
0.75
EV to EBIT
11.61
EV to EBITDA
6.48
EV to Capital Employed
0.87
EV to Sales
0.62
PEG Ratio
0.82
Dividend Yield
NA
ROCE (Latest)
7.51%
ROE (Latest)
0.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
112.20
129.30
-13.23%
Operating Profit (PBDIT) excl Other Income
7.10
12.80
-44.53%
Interest
4.60
6.50
-29.23%
Exceptional Items
-2.90
-4.50
35.56%
Consolidate Net Profit
-1.70
-5.70
70.18%
Operating Profit Margin (Excl OI)
21.40%
52.60%
-3.12%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -13.23% vs -5.62% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 70.18% vs -256.25% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
489.70
558.50
-12.32%
Operating Profit (PBDIT) excl Other Income
23.10
-263.90
108.75%
Interest
15.90
12.50
27.20%
Exceptional Items
-6.90
-56.30
87.74%
Consolidate Net Profit
-3.80
-296.60
98.72%
Operating Profit Margin (Excl OI)
9.20%
-513.60%
52.28%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -12.32% vs -2.24% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 98.72% vs -1,286.40% in Dec 2024
About Boule Diagnostics AB 
Boule Diagnostics AB
Pharmaceuticals & Biotechnology
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
Company Coordinates 
Company Details
Domnarsvgatan 4 , SPANGA None : 163 53
Registrar Details






